VER
Vascular & Endovascular Review

REVIEW ARTICLE

Endovascular Therapies In Peripheral Arterial Diseases: A Systematic Analysis Of Efficacy And Outcomes

Ali Zaib Rasheed

Department of Engineering, Macquarie University, Australia.

Abstract

Endovascular therapy is useful in the treatment of symptomatic peripheral arterial disease (PAD). Recent device advances have resulted in favorable long-term results in iliac arteries as well as minor arteries such as the femoral and popliteal arteries. When standard treatments fail to enhance quality of life and function, endovascular procedures are explored. Critical limb ischemia and acute limb ischemia, on the other hand, endanger the limb and necessitate more immediate revascularization. Endovascular therapies for aortoiliac disease have a longer long-term durability than femoral popliteal disease. In general, infrapopliteal revascularization is reserved for critical and acute limb ischemia. Endovascular treatment relies heavily on balloon angioplasty and stenting. Drug-eluting stents and drug-coated balloons are two new, well-tested inventions. Adjunctive devices for crossing chronic complete occlusions or debulking plaque with atherectomy have received less serious research and have limited roles. Patients undergoing endovascular operations require a planned follow-up care strategy. This involves aggressive treatment of cardiovascular risk factors in order to avoid myocardial infarction and stroke, the two leading causes of mortality. Limb surveillance seeks to detect restenosis and new disease outside the intervening segments, both of which might jeopardize patency and result in recurring symptoms, functional impairment, or a threatened limb. This article discusses the history and recent breakthroughs in endovascular treatment of peripheral vascular disorders, as well as device features and applications. Endovascular therapy of peripheral vascular disease has progressed in lockstep with the introduction of devices such as catheters and stents. As a result, endovascular therapy is currently recommended as the first-line treatment for PAD in recommendations.

Keywords

Endovascular Therapy (ET), Symptomatic Peripheral (SP), Disease (DD), Smart PLS Algorithm

Disclosure: The authors have no conflicts of interest to declare.

Received: 14 August 2022 **Accepted:** 1 july 2023 **Citation:** *Vascular & Endovascular Review* 2023;6:e01. **DOI:** https://doi.org/10.15420/ver.2023.06.02.01

Correspondence: Ali Zaib Rasheed, Department of Engineering, Macquarie University, Australia. Email: Alizaib414@gmail.com

Peripheral arterial disease is a persistent, progressive, incapacitating disease representing the manifestation of systematic atherosclerosis. PAD occurs mainly in lower limbs and is triggered by aortoiliac lesions[1]. The prevalence of PAD intensifies with the age of the population. The symptoms of PAD include leg pain, critical limb ischemia, and intermittent claudication, tissue loss. IC is the initial indication of PAD. PAD patient's risk of cardiovascular-related mortality has significantly multiplied. Peripheral arterial disease has become a worldwide issue and affects 10-20% of the Western community[2]. Some existing methods used to address peripheral arterial disease include surgical intervention and medical management. In surgical treatment, bypass grafting or endarterectomy procedures are involved to treat blood flow in cases where arteries are severely blocked or narrowed. In bypass grafting, a graft is used to redirect the blood flow, and in endarterectomy inner lining of the artery is removed to clear obstruction. Medical management entails non-invasive or pharmacological methods for peripheral arterial disease. Medications may be prescribed to the patient to reduce the severity of unease or complications linked with the disease[3].

Traditional PAD methods involve lifestyle modification, pharmacotherapy, and surgical invention then endovascular therapies evolved as an encouraging substitute, leveraging progress in minimally invasive radiology and vascular health. These methods involve detecting the targeted blood vessels via small incisions, locating catheters, and implementing different devices to resolve stenosis or occlusions. endovascular therapies begin with the development of the angioplasty procedure[4]. The evolution continued with the introduction of stents.

Endovascular aneurysm repair for aortic aneurysm evolved as a meaningful advancement. Further innovations happened to treat PAD. The history of endovascular therapies reflects a progressive shift toward interventional procedures with reduced recovery times and improved outcomes. Endovascular therapies for peripheral arterial disease are used to treat arterial blockages and improve blood flow. Common endovascular therapies for PAD include Angioplasty, in which balloons are typically used to broaden the blocked and narrow arteries to restore blood flow. The balloon is typically part of the catheter, which is a flexible tube-like medical device that is inserted into the body to perform different assessment or therapeutic procedures. These are of various sizes for particular functions and are made up of plastic rubber or silicone. Stenting in which stent- a small mesh-like tube is placed into the blood vessel to give support and

protect it from collapsing. the stent can be bare-metal or drug-eluting. Once the artery is widening with the balloon, the stent is inserted. Stenting procedures start with access via the femoral artery in the groin, a small surgical cut is made and the catheter is placed in the artery.

Another method i.e., Atherectomy in this procedure plaque is removed from the arterial walls. Atherectomy is a condition in which fats are deposits on the inner walls of blood vessels, resulting in narrowing or blockages that can obstruct arteries. Initially, the patient's condition is evaluated via angiography or Doppler ultrasound to detect the target point and severity of blood vessel blockage. The catheter is inserted into the site of arterial blockage then an atherectomy device is introduced into the site of plaque these devices include rotational atherectomy drills, laser catheters, and cutting tools, device-activated to remove or modify the plaque[5]. After the atherectomy device operation, debris is created, and it is necessary to remove this debris from blood vessels to prevent further complications. The last step is confirmation and follow-up imaging to confirm improved arterial blood flow and the success of the operation. Thrombectomy is also an endovascular therapy in which a thrombus (blood clot) is removed from arteries, causing blockage in blood vessels. This procedure is similar to atherectomy. Thrombectomy devices use suction to aspirate the clot, pulling it into a collection chamber for removal.

Thrombectomy is usually used in emergencies to prevent serious complications like tissue damage and organ failure that can occur when blood flow is severely obstructed by a clot[6]. Laser ablation is also used to address peripheral artery disease in which a catheter with a laser fiber is threaded into the targeted blood vessel the laser emits energy which can break down the plaque removing the obstruction from the arteries and restoring the blood flow. This procedure is quite useful for treating vessel blockage that may be difficult to address with traditional methods[7]. Standard endovascular repair is not always possible for patients in some instances. Sometimes the aneurysm is too near to vital aortic branches, or the arteries are too thin or convoluted to allow the catheter used in endovascular surgery to pass through. The patient has three alternatives in these situations: no therapy, open surgery, or sophisticated endovascular repair. Endovascular therapies for difficult disorders have been developed by vascular surgeons at UCSF Health, which are not accessible at other medical centers. Thoracoabdominal aortic aneurysms (TAAA), which include important arteries to the abdominal organs, or arch aortic aneurysms, which involve essential arteries to the brain, may be treated using these modern procedures[8]. Understanding the effectiveness of endovascular therapies in PAD is important for various reasons, firstly it provides physicians with evidence–based guidance in choosing proper interventions for patients with varying intensity of the disease, and it also contributes to the persistent discussion on enhancing healthcare resources. Thirdly, the findings may influence the development of clinical guidelines and protocols, shaping the landscape of peripheral artery disease management on a wider level. Also, it is important to acknowledge certain limitations like differences in study methodologies and technological advancement over time can introduce heterogeneity[9].

Exploration of endovascular therapies in PAD manifests crucial elements of current vascular medicine. In a systematic study, we aim to disclose the effectiveness of therapies and outcomes linked with the interventions. By bridging the gap between conventional and advanced approaches this study play a part in evolving landscape of peripheral artery disease management, having the potential to increase patient care and outcomes[10].

The research describes those Endovascular therapies in peripheral arterial diseases. This research study divided into five specific research chapters first section describe that introduction included objective of research. The second portion represent that literature review the third section present that methods of research the fourth section describe results and its descriptions. The last portion summarized overall research study and present some recommendations.

OBJECTIVE OF RESEARCH:

The main objective of research is determining the endovascular therapies in peripheral arterial diseases.

LITERATURE REVIEW:

Researchers claim that ESWT is a therapy used for treating PAD. The use of this therapy is made under the guidelines provided by PRISMA. clinical outcomes obtained by using ESWT against PAD shows that this therapy is very effective in treating PAD[11] Studies reveal that to assess the benefits of using BVS therapy the clinical outcomes of patient treated through this therapy is assessed. The faster recovery of patients with PAD shows that using BVS therapy is beneficial for the patient[12]. Studies suggest that PAD patients are at higher risk of developing severe cardiovascular diseases Moreover patients having artery disorders in the lower extremities are at higher risk of developing severe limb-associated diseases. PAD is characterized by the disease of arteries The pathophysiology varies in different PAD patients The patients affected with lower or peripheral artery diseases are treated efficiently using antithrombotic therapies Using antithrombotic therapy increases the risk of hemorrhage in PAD patients of proper clinical trials made before providing this therapy to the PAD patients [13]. Studies explain that developing the best anticoagulant against PAD is a great task for physicians. DOACs and VKA are the two major anticoagulants used for treating PAD.

The clinical trials predict that DOACs are ineffective in reducing the risks associated with the lower limb in PAD patient However the higher dose of DOACs increases the risk of bleeding in patients and can life-threatening.to ensure that DOAC anticoagulants are safe for PAD patients and that their appropriate level is given to the patients[14]. Studies predict that PAD is mainly a reason behind the development of serious cardiovascular disorders. The mortality rate due to the cardiovascular diseases induced by PAD increases. The data obtained from the global registry predict that in Taiwan, PAD is an undiagnosed disorder. For identifying the PAD-associated complexity the use of clinical algorithms is made in eth clinical practice. this algorithmic treatment practice is used widely by physicians for managing the clinical PAD patients[15]. Studies explain that injectable biomaterials are sue din ethe treatment therapy of PAD as these biomaterials have high efficacy in treating the severity of PAD patient. The biomaterials are usually made up of nanoparticles. using nanoparticle in the along with gene therapy improves the efficient of therapy-based treatments. DCBs is another method used for treating PAD as it shows great efficacy in treating de novo lesions[16]. Studies predict that a safe and highly efficient technique used for cardiac intervention is objective radial artery For treating the severity of LE- PAD the use of this technique is critical[17] Studies reveal that PVI is provided in different settings to improve the efficiency of treatment processes against

PAD. the tradition PVI providing areas include hospitals whereas the modern areas include OBL and ASC. The shift in various PVI providing settings improves the overall safety of treatment procedures[18].

Studies reveal that peripheral intervascular lithotripsy is one of the latest techniques used in the treatment therapies of PAD [19]. Meta-analysis studies made by scholars on the use of SES therapies predicts that this therapy has high efficiency in treating BTK[20]. Studies shows that foot complications associated with diabetes increases the mortality rate Almost fifty percent of the population having foot complication and diabetes are facing PAD problem. Also, the cardiovascular disease risk increases due to the onset of PAD For providing preventive service to patient of PAD the health guideline are given by IWGDF[21].

Studies highlights that aortoiliac and femoropopliteal artery diseases are treated through the strategies adopted in the endovascular based therapies. The treatment strategies help reduce the limitations of the treatment process. Adopting the most optimal endovascular therapies against PDA improves the quality of the treatment process[22]. Despite the improvement in the endovascular-based therapies, the treatment process against PAD is limited.

Despite aging and diabetes Mellitus the severity of PAD becomes more and the efficacy of treatment therapies become limited. using novel therapies for PAD treatment holds immense significance and has minimum associated limit[23]. Studies elaborate that the contact-free perfusion of tissue is possible using thermal imaging and the HIS technique. These techniques help identify the impact of EVT on PAD patients. The changes in the tissue perfusion are identified using the imaging technique as the imaging technique detects these cages in et perfusions[24]. Studies suggest that two types of surgery-based treatments are employed for treating PAD The first surgery type is ES, and the second type is OS. The surgery based therapies are used based on the safety and effectiveness they provide in treatment procedure[25].studies made by scholars explain that around six percent of world population suffer from PAD. The main cause of PAD in this six percent of the population is due to lower limb atherosclerosis. before the implication of therapies on PAD-affected humans, the therapies are first tested on animal models. The pro-angiogenic factors, when used in the treatment process against PAD in animal models then the results show functional recovery[26]. Scholars claim that patients of PAD are suggested to adopt exercise-based therapy.

The patients following home-based exercise therapy after the EVT show positive outcomes. Pedometers are devices used by PAD recovered patients to carry out home-based exercise therapies[27]. Scholars reveal that is some specific cases the patients of PDA are given with vascular medicines. these medicines show improved results in both sexes Moreover, there is a difference in the response shown by both sexes when given exercise-based therapies. The walking based exercise performed by PDA patients shows improvement in the recovery cycle[28]. Studies show that a low dosage of rivaroxaban plus aspirin is given to PAD patients in combination with innovative pharmacological treatment procedures. the optimized dose of aspirin improves the medical condition of PAD. By using the ABI test on PAD patients, the effectiveness of the PAD screening process can be determined. This test explains that the PAD screening process is very cost-effective [29]. Scholars highlight that ICVD is among one of the major causes of disability in patients with atherosclerosis. Several coronary and cerebral arteries get damaged in atherosclerosis. The lower limb PDA complexity is observed in patients with PAD. Also, the progenesis of PDA is evaluated through certain treatment-based clinical procedures[30].

Applications:

- For testing certain complexities associated with endovascular disease, the use of endovascular therapy provides great advantages. Endovascular therapies are considered more effective than open surgical therapies as they are performed using local anesthesia. the mortality rate of vascular disease affected patients decreases by using catheter-based therapies instead of using open surgery. The advancement in the MRA and CTA technologies have improved the anatomy process of vascular tissues. These therapy technologies are designed to provide 3D images of plaque formation and vessels overlapping. These noninvasive technologies improve the treatment process by providing images of the vascular structures. images obtained related to the pathophysiology of vascular tissues of PDA patients determine the extent of severity of diseases. by knowing about the structure of the peripheral vascular tissues of arteries, a proper therapy technology can be adopted in clinical procedures.

- The ABI test is done to provide efficient therapies-based treatment to PAD patients. This test identifies if the person is affected with PAD or not. PAD patients having symptoms of PAD mostly undergo this test. If the ABI test's value is less than 0.9, then the patient is considered borderline abnormal. The patient is considered normal if the ABI value is greater than .0.9. While an ABI greater than 1.4 shows that a person is affected with PAD and has a severe type of disease complexity. By identifying the patient severity based on the ABI test, proper treatment therapies can be adopted. before adopting any treatment therapy against PDA patients, the ABI test is critical in every clinical trial.

- DCB is a modern therapy against PDA. This therapy is characterized by its ability to deliver drugs to the targeted artery using the ballon. The deliverance of the drug to the targeted artery allows for the maximum absorption of the drug at the artery's wall. around 10 types of DCBS therapies are used in Europe to improve the treatment process against PDA. Three of the 10 DCB types are most commonly used in the US and other states. These three include DCD Stellarex, DCB Admiral, and Lutonix DCB. The suitable range of the paclitaxel dose is around two to three micrograms. whereas the diameter of balloons available for therapeutic purposes ranges from four to seven millimeters. DCB technique is more effective than the traditional BA technique because of the targeted therapy it provides. For treating FP-ISR lesions, DCB therapy is used in combination with orbital atherectomy.

- Another DCB-based therapy for PDA-related disease treatment is Ranger DCB. This therapy uses a coating of proprietary Transpax™. Using this coating system improves the deliverance of drugs to the damaged arteries. The recovery response of patients of PDA treated through the ranger DCB is enhanced at an exponential rate. The patients receiving the ranger DCB base therapy showed ninety percent improvement. the ranger DCB treatment therapy is regarded as the next-generation technique for treating PDA as it is specialized for transferring the drug to the lesion. The loss of drug during the insertion

process is minimized through the use of ranger DCB.

- In PDA patients, the medial calcification is related to the onset of other diseases like diabetes mellitus. The calcification of vessels in PDA patients is one of the obstacles for DCB-based therapy and that leads to severe complications in the treatment process. To remove the calcified substances from the vessels, an atherectomy device is used before using the DCB technique. This device removes calcified substances from the vessels to prepare them to undergo DCB therapy. the efficiency of the Atherectomy device is predicted by its ability to remove the plaques from the obstructed vessels.

- Another very prominent therapy used in the treatment of PDA patients to remove plaques from arteries is shockwave lithotripsy. This technique comprises of Cather ballon that is made up of electrodes. The electrodes produce shockwaves that remove the plaque from the arterial system. The activation of lithotripsy electrodes helps in generating some mechanical energy that breaks the calcified plaque into the process. The shockwave system is highly designed with a low-pressure system to minimize the chances of vascular injury during the treatment process. The number of impulses delivered for one treatment cycle is therapy. Moreover, after completing ten treatment cycles, the catheter expires.

- The patient of CLI requires proper treatment to save the disease from getting severe. The CLI patient faces other diseases as well and is said to have multi-level diseases. The patient of CLI having diabetes has three vessels below the knee diseases. the small vessel ulceration is also observed in CLI patients having diabetes meultus. To deal with severe CLI diseases, BASIL therapy is used in clinical processes. The recovery outcome of a patient getting angioplasty therapy shows improved results compared to a patient getting open-end surgery. The outcome thus shows that BASIL is a more effective treatment therapy approach than open-end surgery for CLI treatment.

- In most cases, they are provided with cilostazol after getting EVT to PDA patients. Cilostazol is usually made to improve the treatment process's overall efficiency and lower the risk associated with amputation. the anti-platelet effects related to cilostazol make it useful for inhibiting phosphodiesterase. The restenosis is treated through the use of cilostazol. Cilostazol is officially regarded as the first-line therapy for PDA-related symptoms as it improves the quality of life of PDA patients. The main function of cilostazol usage after the EVT in PDA patients is improved blood flow in vessels.

- To achieve excellent treatment outcomes after treating PVD patients, clinical physicians make use of aspirin. Aspirin is used as an anti-platelet agent that has a special therapeutic ability in managing patients with PVD. Patients with PVD having a history of stroke show effective responses when treated using aspirin in the prevention therapy. The use of Aspirin in therapy-based treatment against AAA shows a significant reduction in vascular tissue-related events in patients with PVD.

DESCRIPTIVE STATISTIC:

Table 1

Name	No.	Mean	Median	Scale min	Scale max	Standard deviation	Excess kurtosis	Skewness	Cramér-von Mises p value
ET1	0	1.816	2.000	1.000	4.000	0.896	-0.550	0.731	0.000
ET2	1	1.714	2.000	1.000	4.000	0.756	0.241	0.836	0.000
ET3	2	1.857	2.000	1.000	5.000	0.857	2.621	1.290	0.000
ET4	3	1.490	1.000	1.000	3.000	0.576	-0.453	0.703	0.000
ET5	4	1.612	2.000	1.000	3.000	0.664	-0.597	0.648	0.000
PAD1	5	1.694	2.000	1.000	4.000	0.676	1.339	0.884	0.000
PAD2	6	1.490	1.000	1.000	3.000	0.539	-1.002	0.445	0.000
PAD3	7	1.714	2.000	1.000	3.000	0.700	-0.861	0.474	0.000
PAD4	8	1.694	2.000	1.000	3.000	0.613	-0.585	0.303	0.000
PAD5	9	1.592	2.000	1.000	3.000	0.636	-0.535	0.623	0.000

The above results represent that descriptive statistic analysis results in the mean values, the median rates, the minimum values, and the maximum values of each indicator. The result also describes that skewness rates and probability values of each variable included independent and dependent. The ET1, ET2, ET3, and ET4 are all considered independent variables. According to the result, their mean values are 1.816, 1.714, 1.857, also that 1.490. These all-present positive average values of the mean. The result describes that standard deviation rates of ET are 89%, 75%, 85%, and 57% positive deviate from the norm.

The overall probability value is 0.000 its, shows 100% significantly level the skewness rates f ET are 73%, 83%, 1.290 and 70% respectively. According to the result, the PAD1, PAD2, PAD3, PAD4, and PAD5 these are all considered as dependent indicators result represent that mean values are 1.694, 1.490, 1.694, 1.592 these are all show positive average values. The standard deviation rates are 53%, 70%, 61%, and 63% deviate from the mean. The skewness values are 44%, 47%, 30%, and 62% skewness rates of each indicator. According to the result, the overall minimum value is 1.000, the maximum value is 3.000, and the median rate is 2.000, respectively. Endovascular surgery is a novel, less intrusive treatment used to treat blood vessel disorders such as aneurysms, which are swellings or "ballooning" of the blood arteries.

To access the blood vessels, a tiny incision is made near each hip. A catheter, a long, narrow, flexible tube, is used to implant an endovascular graft, which is a unique fabric tube device framed with stainless steel self-

expanding stents through the arteries and into the aorta. When the graft is in place, it swells and shuts off the aneurysm, stopping blood from flowing into it.

The graft is permanently implanted in the aorta. Previously, this disease was treated with open surgery, which required an incision in the side of the chest or breastbone and a lengthy recuperation period. Patients usually stay in the hospital for seven to ten days after open surgery and recuperate for three months. Endovascular surgery, a less invasive alternative to open surgery, has several advantages, including a faster recovery period, less discomfort, local or regional anesthesia rather than general anesthesia, smaller incisions, less stress on the heart, and fewer hazards for individuals with underlying medical issues. Patients who require surgery but are at high risk of complications due to other disorders may benefit from this technique.

CORRELATION COEFFICIENT:

Table 2

	ET1	ET2	ET3	ET4	ET5	PAD1	PAD2	PAD3	PAD4	PAD5
ET1	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
ET2	-0.138	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
ET3	0.471	-0.063	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
ET4	-0.182	0.040	0.100	1.000	0.000	0.000	0.000	0.000	0.000	0.000
ET5	0.429	-0.261	0.333	0.070	1.000	0.000	0.000	0.000	0.000	0.000
PAD1	-0.093	-0.211	-0.075	-0.034	-0.173	1.000	0.000	0.000	0.000	0.000
PAD2	0.059	-0.207	0.328	0.279	0.074	0.467	1.000	0.000	0.000	0.000
PAD3	-0.149	0.116	-0.136	0.094	-0.063	0.203	0.155	1.000	0.000	0.000
PAD4	0.009	-0.013	0.305	0.078	0.009	-0.128	0.083	-0.442	1.000	0.000
PAD5	-0.167	-0.158	-0.107	-0.178	0.060	-0.338	-0.191	0.196	-0.059	1.000

The above result represents that correlation coefficient analysis related to dependent and independent indicators. The ET2 shows a -0.138 negative correlation with ET1, the ET3 shows a 47% positive correlation with ET1, and the -0.063 negative correlation with them. PAD1, PAD2, and PAD3 show that -0.093, 0.059, -0.149, and 16% correlation with them. the result describes that -0.167, -0.107, -0.178, also that -0.338, respectively. Interventional therapy is required for PAD when patients acquire symptoms such as discomfort or tissue loss owing to a lack of circulation. Endovascular therapies are typically employed when patients have failed conservative therapy, such as medication and supervised exercise, and are facing a constraint in their lifestyle as a result of their condition, such as being unable to work.

An endovascular operation is conducted inside your arteries with the use of a thin, long tube known as a catheter. The surgeon then directs the catheter through a tiny incision in the groin to the blocked region in the blood artery. The surgeon will next execute an endovascular procedure, such as balloon angioplasty or stenting. The clogged artery is opened using balloon angioplasty by forcing plaque against the vessel wall with a balloon placed through a catheter. Following angioplasty, a stent or mesh wire tube may be inserted in the artery to support the cleaned conduit and maintain it open. Endovascular techniques like these benefit a wide range of patients. They assist younger patients who desire to return to work as soon as possible. A minimally invasive method can allow qualified patients to return to work in as little as two weeks, compared to six to eight weeks with open surgery. Endovascular therapies are also an option for individuals who have undergone previous open operations and have been warned they are too high a risk for another open surgery.

At Metro Health, we usually go with the least intrusive alternative first, if it is the best and safest option for the patient. There is a probability that we have a less invasive strategy that works. Our vascular surgeons consult with patients on an individual basis to evaluate whether endovascular therapy is the best option for them. We weigh the risks and advantages of each therapy, considering the patient's arteries, physical condition, and how comfortable the patient and doctor are with the various alternatives.

SMART PLS ALGORITHM:



The above model describes the algorithm model between ET and PAD the -0.509, -0.452, 0.256, -0.528 shows that some negative and some positive values of each other. The result describes that 0.439, -0.640, 0.374, 0.733 also that -0.207 shows that negative also that positive rates of each variable.

CONCLUSION:

For some lesions, endovascular treatment has numerous unique benefits versus open surgical revascularization.6,7 It is conducted under local and anesthesia, allowing it to treat individuals who are at high risk for general an aesthesia. When compared to open surgical revascularization, catheter-based treatment has exceptionally low morbidity and mortality. Patients are ambulatory on the day of treatment following successful percutaneous revascularization, and unlike after vascular surgery, they may generally return to regular activities within 24 to 48 hours of a simple operation. Endovascular treatments do not usually exclude or affect later surgery, and they can be repeated if necessary.

Over the last several decades, several disciplines, including interventional cardiology, have contributed to the growth of the area of peripheral vascular intervention.8 Recognising an unmet need for a trained cadre of doctors to care for PAD patients led to the creation of a core curriculum document (COCATS-11)9 and a multispecialty societal competency statement.10 Guidelines and recommendations for the diagnosis and treatment of PAD have been released by the American Heart Association and the American College of Cardiology.

The availability of high-quality noninvasive diagnostic imaging and increasing patient knowledge of PAD have boosted the number of people seeking treatment for PAD. For measuring the research study used smart PLS software and generate informative results included descriptive statistic, correlation coefficients, also that smart PLS Algorithm model. The overall research concluded that direct and significant link between them.

Endovascular therapy of lower-extremity PAD is evolving, with emerging methods ranging from local medication administration to bioabsorbable stents expected to increase acute success rates and safety, as well as long-term durability. Percutaneous techniques will continue to be used instead of open surgery. The current evidence bases to support decision making is quite limited when compared to the field of coronary intervention, and reporting standards for PAD intervention are generally lacking, but there is a growing determination on the part of physician-investigators, government regulators and payers, and industry to undertake the difficult but necessary task of collecting more definitive data.

REFERENCES

1. U. Campia, M. Gerhard-Herman, G. Piazza, and S. Z. J. T. A. j. o. m. Goldhaber, "Peripheral artery disease: past, present, and future," vol. 132, no. 10, pp. 1133-1141, 2019.
2. G. H. Bevan, K. T. J. A. White Solaru, thrombosis,, and v. biology, "Evidence-based medical management of peripheral artery disease," vol. 40, no. 3, pp. 541-553, 2020.
3. C. Zito, R. Manganaro, S. Carerj, F. Antonini-Canterin, and F. J. J. o. c. e. Benedetto, "Peripheral artery disease and stroke," vol. 30, no. Suppl 1, pp. S17-S25, 2020.
4. D. Guez *et al.*, "Recent trends in endovascular and surgical treatment of peripheral arterial disease in the medicare population," vol. 214, no. 5, pp. 962-966, 2020.
5. G. Korosoglou, S. Giusca, M. Andrassy, and M. J. V. E. R. Lichtenberg, "The role of atherectomy in peripheral artery disease: current evidence and future perspectives," vol. 2, pp. 12-18, 2019.
6. J. Liu *et al.*, "Percutaneous mechanical thrombectomy using Rotarex catheter in peripheral artery occlusion diseases–Experience from a single center," vol. 27, no. 2, pp. 199-203, 2019.
7. F. J. D. Stanek and I. Radiology, "Laser angioplasty of peripheral arteries: basic principles, current clinical studies, and future directions," vol. 25, no. 5, p. 392, 2019.
8. D. Pastori *et al.*, "Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis," vol. 120, no. 05, pp. 866-875, 2020.
9. M. P. Bonaca *et al.*, "Rivaroxaban in peripheral artery disease after revascularization," vol. 382, no. 21, pp. 1994-2004, 2020.
10. J. A. Beckman, P. A. Schneider, and M. S. J. C. r. Conte, "Advances in revascularization for peripheral artery disease: revascularization in PAD," vol. 128, no. 12, pp. 1885-1912, 2021.
11. Z. Munir *et al.*, "Evaluation of the Effects of Extracorporeal Shockwave Therapy in Patients With Peripheral Arterial Disease: A Meta-Analysis of Randomized Control Trials," *Cureus,* vol. 15, no. 2, 2023.
12. W. Fan *et al.*, "Efficacy and safety of absorb everolimus-eluting bioresorbable vascular scaffold in peripheral artery disease: a single-arm meta-analysis," *Journal of Endovascular Therapy,* vol. 30, no. 5, pp. 651-663, 2023.
13. M. E. Canonico *et al.*, "Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions," *Journal of Cardiovascular Development and Disease,* vol. 10, no. 4, p. 164, 2023.
14. E. Pomozi *et al.*, "Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis," *Journal of Cardiovascular Development and Disease,* vol. 10, no. 2, p. 65, 2023.
15. J.-K. Lee *et al.*, "Referral, diagnosis, and pharmacological management of peripheral artery disease: perspectives from Taiwan," *Acta Cardiologica Sinica,* vol. 39, no. 1, p. 97, 2023.
16. S. U. R. Qamar, L. Spahić, L. Benolić, M. Zivanovic, and N. Filipović, "Treatment of Peripheral Artery Disease Using Injectable Biomaterials and Drug-Coated Balloons: Safety and Efficacy Perspective," *Pharmaceutics,* vol. 15, no. 7, p. 1813, 2023.
17. S. Maximus, M. Kwong, J. Harding, and M. Mell, "Radial arterial access is a safe alternative to brachial artery and femoral artery access for endovascular lower extremity peripheral arterial disease," *Journal of Vascular Surgery,* vol. 77, no. 3, pp. 870-876, 2023.
18. C. Y. Chow, A. Mathlouthi, S. Zarrintan, E. P. Swafford, J. J. Siracuse, and M. B. Malas, "Outcomes of elective peripheral endovascular interventions for peripheral arterial disease performed in hospital outpatient departments, ambulatory surgical centers and office-based labs," *Journal of Vascular Surgery,* vol. 77, no. 6, pp. 1732-1740, 2023.
19. C. Umeh *et al.*, "C-29| Peripheral Artery Intravascular Lithotripsy: A Systematic Review," *Journal of the Society for Cardiovascular Angiography & Interventions,* vol. 2, no. 3, 2023.
20. K. Y. Fong, L. Xin, J. Ng, S. E. Loh, J. J. Ng, and A. M. Choong, "A systematic review and meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial disease," *Journal of Vascular Surgery,* vol. 77, no. 4, pp. 1264-1273. e3, 2023.
21. R. Fitridge *et al.*, "The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer," *Journal of vascular surgery,* vol. 78, no. 5, pp. 1101-1131, 2023.
22. D. Koeckerling *et al.*, "Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis," *European Heart Journal,* vol. 44, no. 11, pp. 935-950, 2023.
23. A. Arabzadeh *et al.*, "Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review," *Advanced Pharmaceutical Bulletin,* vol. 13, no. 2, p. 259, 2023.
24. S. F. Kleiss *et al.*, "Detecting changes in tissue perfusion with hyperspectral imaging and thermal imaging following endovascular treatment for peripheral arterial disease," *Journal of Endovascular Therapy,* vol. 30, no. 3, pp. 382-392, 2023.
25. G. Wang, H. Li, B. Chen, P. Guo, and H. Zhang, "Amputation and limb salvage following endovascular and open surgery for the treatment of peripheral artery illnesses: A meta-analysis," *International Wound Journal,* 2023.
26. K. A. Webster, "Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease," 2023.
27. K. Kawamura *et al.*, "Association between home-based exercise using a pedometer and clinical prognosis after endovascular treatment in patients with peripheral artery disease," *Journal of Cardiology,* vol. 81, no. 2, pp. 222-228, 2023.
28. S. Lanzi, A. Pousaz, L. Calanca, and L. Mazzolai, "Sex-based differences in supervised exercise therapy outcomes for symptomatic peripheral artery disease," *Vascular Medicine,* vol. 28, no. 2, pp. 147-149, 2023.
29. Y. Xing, Y. Qiu, L. Yang, Z. Yuan, and Y. Wang, "Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model," *International Journal of Cardiology,* vol. 371, pp. 420-426, 2023.
30. L.-g. Li and X. Ma, "Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease," *European Journal of Medical Research,* vol. 28, no. 1, p. 93, 2023.